Optimizing Prostate Biopsy Techniques

Journal of Urology

Volumn 177, Issue 6, 2007, Pages 1976-1977

  Kibel, Adam S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE;

BIOPSY TECHNIQUE; CANCER DIAGNOSIS; CANCER INHIBITION; CANCER SIZE; CONCEPTUAL FRAMEWORK; EDITORIAL; FAMILY HISTORY; GLEASON SCORE; HAZARD RATIO; HUMAN; HYPOTHESIS; MATHEMATICAL MODEL; NEEDLE BIOPSY; NOMOGRAM; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CARCINOMA; SECONDARY ANALYSIS; TUMOR LOCALIZATION; TUMOR VOLUME; UROLOGY;

BIOPSY; CHOLESTENONE 5 ALPHA-REDUCTASE; HUMANS; MALE; ORGAN SIZE; PREDICTIVE VALUE OF TESTS; PROSTATIC NEOPLASMS; TUMOR BURDEN;

EID: 34248172352     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2007.03.073     Document Type: Editorial

References (10)

1. Hodge K.K., McNeal J.E., Terris M.K., and Stamey T.A. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142 (1989) 71
2. Uzzo R.G., Wei J.T., Waldbaum R.S., Perlmutter A.P., Byrne J.C., and Vaughan Jr. E.D. The influence of prostate size on cancer detection. Urology 46 (1995) 831
3. Gore J.L., Shariat S.F., Miles B.J., Kadmon D., Jiang N., Wheeler T.M., et al. Optimal combinations of systematic sextant and laterally directed biopsies for the detection of prostate cancer. J Urol 165 (2001) 1554
4. Presti Jr. J.C., Chang J.J., Bhargava V., and Shinohara K. The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 163 (2000) 163
5. Furuno T., Demura T., Kaneta T., Gotoda H., Muraoka S., Sato T., et al. Difference of cancer core distribution between first and repeat biopsy: In patients diagnosed by extensive transperineal ultrasound guided template prostate biopsy. Prostate 58 (2004) 76
6. Remzi M., Fong Y.K., Dobrovits M., Anagnostou T., Seitz C., Waldert M., et al. The Vienna nomogram: validation of a novel biopsy strategy defining the optimal number of cores based on patient age and total prostate volume. J Urol 174 (2005) 1256
7. Epstein J.I., Walsh P.C., Carmichael M., and Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368
8. Andriole G., Bostwick D., Brawley O., Gomella L., Marberger M., Tindall D., et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol 172 (2004) 1314
9. Thompson I.M., Goodman P.J., Tangen C.M., Lucia M.S., Miller G.J., Ford L.G., et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 349 (2003) 215
10. Klein E.A., Tangen C.M., Goodman P.J., Lippman S.M., and Thompson I.M. Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited. J Clin Oncol 23 (2005) 7460